Shahzad Ghanbarian, Gavin W K Wong, Mary Bunka, Louisa Edwards, Sonya Cressman, Tania Conte, Sandra Peterson, Rohit Vijh, Morgan Price, Christian Schuetz, David Erickson, Linda Riches, Ginny Landry, Kim McGrail, Jehannine Austin, Stirling Bryan
BACKGROUND: Major depressive disorder (MDD) is a common, often recurrent condition and a significant driver of healthcare costs. People with MDD often receive pharmacological therapy as the first-line treatment, but the majority of people require more than one medication trial to find one that relieves symptoms without causing intolerable side effects. There is an acute need for more effective interventions to improve patients' remission and quality of life and reduce the condition's economic burden on the healthcare system...
March 26, 2024: PharmacoEconomics Open